Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Formoterol Fumarate, Formoterol (Oxis Turbuhaler), Formoterol (OT), Formoterol (Pressair®), Perforomist® Inhalation Solution
Formoterol · 4 trials · 3 indications
Mean change from Baseline
Change from baseline
Change from baseline
Change from baseline
Change from baseline
Change from baseline
Change from baseline
Change from baseline
Change from baseline
Change from baseline
Change from baseline
Change from baseline
Change from Baseline
Change from baseline
Change from baseline
Change from baseline
Change from baseline
Change from baseline
Change from baseline
Change from baseline
Change from baseline
Change from baseline
Change from baseline
Change from baseline
Change from baseline
Change from baseline
Change from baseline
Change from baseline
To assess the bronchodilation of 3 doses of formoterol fumarate (6 μg, 12 μg and 24 μg) twice daily (BID administered via Pressair® compared to placebo and to open-label nebulised formoterol fumarate(20 μg). Pre-dose spirometry was performed before the morning daily dose at Day 1 and Day 7 of each treatment period. Two sets of measurements were performed during the hour preceding the scheduled morning study drug administration, allowing approximately 30 minutes between them. Note: Perforomist® 40 μg treatment periods lasted for 1 day only. Hence, was not included in the calculation.
FEV1(Forced Expiratory Volume in 1 second) measured by spirometry 5 minutes post dose, percentage change versus pre dose FEV1
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Formoterol 9 μg/dose |
| Formoterol 6 μg | EXPERIMENTAL | Participants received formoterol fumarate 6 μg administered via Pressair twice daily (BID). |
| Formoterol 12 μg | EXPERIMENTAL | Participants received formoterol fumarate 12 μg administered via Pressair BID. |
| Formoterol 24 μg | EXPERIMENTAL | Participants received formoterol fumarate 24 μg administered via Pressair BID. |
| Placebo | PLACEBO_COMPARATOR | Participants received placebo to formoterol fumarate administered via Pressair BID. |
| Formoterol 20 μg | EXPERIMENTAL | Participants received Perforomist inhalation solution and were instructed to take one puff from each of the two Pressair inhalers or to inhale one vial from the Perforomist 20 μg inhalation solution BID for 7 ± 1 consecutive days. |
| Formoterol 40 μg | EXPERIMENTAL | Participants received Perforomist 40 μg (2 vials of Performist 20 μg) as a single dose of administration. |
| Formoterol, then Salmeterol, then Placebo | EXPERIMENTAL | Formoterol Turbuhaler 9 μg and Placebo Diskus first, then Salmeterol Diskus 50 μg and Placebo Turbuhaler, then Placebo Diskus and Placebo Turbuhaler |
| Salmeterol, then Palcebo, then Formoterol | EXPERIMENTAL | Salmeterol Diskus 50 μg and Placebo Turbuhaler first, then Placebo Diskus and Placebo Turbuhaler, then Formoterol Turbuhaler 9 μg and Placebo Diskus |
| Placebo, then Formoterol, then Salmeterol | EXPERIMENTAL | Placebo Diskus and Placebo Turbuhaler first,then Formoterol Turbuhaler 9 μg and Placebo Diskus, then Salmeterol Diskus 50 μg and Placebo Turbuhaler |
| Formoterol, then Placebo, then Salmeterol | EXPERIMENTAL | Formoterol Turbuhaler 9 μg and Placebo Diskus first, then Placebo Diskus and Placebo Turbuhaler, then Salmeterol Diskus 50 μg and Placebo Turbuhaler |
| Salmeterol, then Formoterol, then Placebo | EXPERIMENTAL | Salmeterol Diskus 50 μg and Placebo Turbuhaler first, then Formoterol Turbuhaler 9 μg and Placebo Diskus, then Placebo Diskus and Placebo Turbuhaler |
| Placebo, then Salmeterol, then Formoterol | EXPERIMENTAL | Placebo Diskus and Placebo Turbuhaler first, then Salmeterol Diskus 50 μg and Placebo Turbuhaler, then Formoterol Turbuhaler 9 μg and Placebo Diskus |
| Name | Type | Description |
|---|---|---|
| Formoterol (OT) | DRUG | 9 μg/dose, Inhaled, twice daily for 52 weeks |
| formoterol | DRUG | - |
| budesonide/formoterol | DRUG | - |
| Formoterol fumarate (6 μg) | DRUG | Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI) |
| Formoterol furmarate (20 μg) | DRUG | Oral Inhalation (via a standard jet nebulizer connected to an air compressor. |
| Placebo for formoterol fumarate | DRUG | Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI) |
| Formoterol fumarate (12 μg) | DRUG | Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI) |
| Formoterol fumarate (40 μg) | DRUG | Oral Inhalation (via a standard jet nebulizer connected to an air compressor. |
| Salmeterol | DRUG | Salmeterol Diskus 50 μg and Placebo Turbuhaler |
| Placebo | DRUG | Placebo Diskus and Placebo Turbuhaler |
Inclusion Criteria: * Outpatients, men or women ≥ 40 years * A clinical diagnosis of COPD according to guidelines, and current COPD symptoms. * Post-bronchodilator FEV1 \< 80% of predicted normal value and FEV1/FVC \< 70%, post-bronchodilator Exclusion Criteria: * A history and/or current clinica...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
Formoterol is used to treat asthma and chronic obstructive pulmonary disease, or COPD. It is a long-acting inhaled bronchodilator developed by AstraZeneca PLC. In COPD it helps keep the airways open, and in asthma it is studied as part of inhaled treatment regimens. It is given by inhalation through devices such as the Turbuhaler.
Formoterol works as an agonist at ADRB2, the beta-2 adrenergic receptor. By activating this receptor on airway smooth muscle, it produces bronchodilation and helps relieve airflow obstruction in asthma and COPD. This receptor target class, a beta-2 agonist, is the basis for its use as a long-acting bronchodilator in respiratory disease.
Formoterol is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca has run clinical studies of the drug in asthma and COPD, including the ACHIEVE Duaklir USA Phase IIb dose ranging study and the SMILDA study in allergic asthma patients.
Formoterol has been studied in Phase 3 clinical development for asthma and COPD. Completed Phase 3 trials include NCT01047553, which evaluated an 18 microgram daily dose in Japanese COPD patients, and NCT00288379, the SMILDA study in allergic patients with mild asthma. It remains an investigational asset in these programs.
Formoterol has completed clinical trials including NCT02796651, a Phase 2 dose ranging study in COPD in the United States; NCT01048333, a Phase 2 onset of effect study in COPD in Italy, Spain and Sweden; NCT01047553, a Phase 3 COPD study in Japan; and NCT00288379, a Phase 3 asthma study in Sweden.
Yes. Formoterol is also known as formoterol fumarate, formoterol fumarate 6 microgram, and Formoterol (Oxis Turbuhaler) or Formoterol (OT). These names refer to the same active drug and its inhaled Turbuhaler formulation, so searches for any of these terms describe the same AstraZeneca respiratory asset.